New York, New York (PRWEB) April 27, 2014
In just over a month, nearly 200 new Lipitor lawsuits (http://www.thelipitorlawsuit.com/ ) have been filed in a federal litigation underway in the U.S. District Court, District of South Carolina on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the statin medication, Bernstein Liebhard LLP reports.
According to an update issued on April 15th by the U.S. Judicial Panel on Multidistrict Litigation (JPML) a total of 464 claims alleging new-onset diabetes are now pending in the federal proceeding. Court records indicate that these Lipitor lawsuits were filed on behalf of individuals who claim that its manufacturer, Pfizer Inc., failed to adequately warn about the drugs potential to cause the disease, and concealed knowledge of that risk to protect sales of the drug. The Panels most recent update represents significant growth in the federal litigation, as a previous update issued on March 13th indicated that 270 cases had been filed at that time. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
Our Firm continues to evaluate potential legal claims that allege a connection between Lipitor and diabetes. We are not surprised to see that filings are increasing at a steady rate, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs, including Lipitor. The Firm is currently offering free and confidential case evaluations to individuals who were diagnosed with Type 2 diabetes after taking the statin.
Lipitor Diabetes Lawsuits
Lipitor lawsuits began to mount shortly after a public health alert was issued by the U.S. Food and Drug Administration (FDA) regarding an association between cholesterol-lowering statins like Lipitor and diabetes. The February 2012 warning followed the findings of a study published a month earlier in JAMA: Internal Medicine that suggested an increased risk for Type 2 diabetes in post-menopausal women taking Lipitor and similar medications.*
The FDA action required all cholesterol statin manufacturers to adjust product labeling to note their possible association with the disease. However, Plaintiffs in Lipitor-lawsuits allege that the information added to the Lipitor label following the FDA mandate remains insufficient.
In May 2013, research published by the British Medical Journal lent further evidence to a link between Lipitor and diabetes, when researchers found a 22 percent increased risk for the disease in patients who took the medication atorvastatin, the generic version of Lipitor.**
Individuals who developed new-onset Type 2 diabetes allegedly stemming from their use of Lipitor may be eligible to seek compensation for out-of-pocket medical expenses and lost wages, as well as any pain and suffering they may have endured as a result of their situation. Learn more about the association between Lipitor and diabetes by visiting Bernstein Liebhard LLPs website. To arrange for a free legal review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
**bmj.com/content/346/bmj.f2610, BMJ, May 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorney fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery.
As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiffs recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016